Project Grant R01HL183056
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $771K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Regents of the University of Michigan $2,257,845 under a Project Grant (R01HL180433) on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a real-time, non-invasive micro-rheology technique to characterize aging thrombi using ultrasound-responsive nanodroplets. The nanodroplets phase-transition into microbubbles when exposed to focused ultrasound above a threshold amplitude—a...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $567,166 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tunable multi-thrombolytic nanoformulations for treating ischemic stroke with minimal hemorrhagic risk. The research addresses limitations of current thrombolytic therapy—tissue plasminogen activator (tPA) carries serious intracranial hemorrhage complications, while plasmin, a more effective...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $429,000 Project Grant to the Regents of the University of Michigan on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a rapid, non-contrast, low-field magnetic resonance imaging (MRI) pipeline for detecting pulmonary embolism (PE). The project, which extends through July 31, 2027, focuses on creating an efficient 3D, contrast-free MRI protocol utilizing...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,200 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial cell fate switches and dysfunction driven by fibrotic matrix remodeling. The research uses mouse models and an in vitro human microphysiological system of arteriole and venule-scale microvessels embedded within tunable stromal mimetic matrices to demonstrate how fibrotic physical cues...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $903,185 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL183614) to develop a Preemie ECMO System addressing respiratory failure in premature infants for whom extracorporeal membrane oxygenation is currently contraindicated. Work is performed at the University of Michigan in Ann Arbor, Michigan, with a period of performance through April 30,...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $803,081 on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an artificial intelligence system for improved diagnosis, prognosis, and management of acute pulmonary embolism. The recipient will build a vision foundation model integrating high-dimensional computed tomography pulmonary angiography (CTPA) imaging features,...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $661,884 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop lung ultrasound surface wave elastography (LUSWE) as a diagnostic and assessment tool for diffuse pulmonary parenchymal disease. The project aims to develop novel technology analyzing lung mass density and viscoelasticity in addition to surface wave speed to create a noninvasive screening tool for early identification of...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...
- The National Heart, Lung, and Blood Institute awarded Lawrence Technological University $444,589 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop multiscale computational modeling for assessing shear-induced bleeding risk in blood-contacting medical devices. The research addresses device-induced complications in blood-contacting medical devices used to manage and treat heart conditions. The project develops physics-based computational models to...
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...